These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21070297

  • 1. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

  • 2. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010 Oct; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 3. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 4. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Metabolism; 2011 Mar; 60(3):421-9. PubMed ID: 20423740
    [Abstract] [Full Text] [Related]

  • 5. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 6. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Intern Med; 2010 Nov; 49(16):1717-25. PubMed ID: 20720348
    [Abstract] [Full Text] [Related]

  • 7. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [Abstract] [Full Text] [Related]

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.
    Intern Med; 2009 Apr; 48(5):265-71. PubMed ID: 19252346
    [Abstract] [Full Text] [Related]

  • 11. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 12. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [Abstract] [Full Text] [Related]

  • 13. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Endocr J; 2010 Oct; 57(9):777-86. PubMed ID: 20683173
    [Abstract] [Full Text] [Related]

  • 14. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 15. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [Abstract] [Full Text] [Related]

  • 16. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [Abstract] [Full Text] [Related]

  • 17. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 18. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 19. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, Sibutramine/Diabetes Clinical Study Group.
    Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
    [Abstract] [Full Text] [Related]

  • 20. Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
    Al-Tahami BAM, Al-Safi Ismail AA, Sanip Z, Yusoff Z, Shihabudin TMT, Singh TSP, Rasool AHG.
    J Nippon Med Sch; 2017 Jun; 84(3):125-132. PubMed ID: 28724846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.